Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, Waultier-Rascalou A, di Blasi R, Houot R, Souchet L, Roos-Weil D, Uzunov M, Quoc SN, Jacque N, Boussen I, Gauthier N, Ouzegdouh M, Blonski M, Campidelli A, Ahle G, Guffroy B, Willems L, Corvilain E, Barrie M, Alcantara M, le Garff-Tavernier M, Psimaras D, Weiss N, Baron M, Bravetti C, Hoang-Xuan K, Davi F, Shor N, Alentorn A, Houillier C. Choquet S, et al. Among authors: ouzegdouh m. Am J Hematol. 2024 Apr 8. doi: 10.1002/ajh.27316. Online ahead of print. Am J Hematol. 2024. PMID: 38586986
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation.
Forgeard N, Baron M, Caron J, Boccon-Gibod C, Krzisch D, Guedes N, Morel V, Jacque N, Ouzegdouh M, Choquet S, Bravetti C, Nguyen-Khac F, Chapiro E, Leblond V, Roos-Weil D. Forgeard N, et al. Among authors: ouzegdouh m. Haematologica. 2022 Nov 1;107(11):2720-2724. doi: 10.3324/haematol.2022.281053. Haematologica. 2022. PMID: 35833301 Free PMC article. No abstract available.
Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Legendre P, Chahwan D, Marjanovic Z, Vignon M, Hermine O, Lortholary O, Morelle G, Darrodes M, Kahn JE, Ouzegdouh M, Chaibi P, Montestruc F, Caumont-Prim A, Le Jouan M, Hassani Y, Godeau B, Durand-Zaleski I, Mouthon L. Legendre P, et al. Among authors: ouzegdouh m. Clin Immunol. 2020 Jun;215:108419. doi: 10.1016/j.clim.2020.108419. Epub 2020 Apr 11. Clin Immunol. 2020. PMID: 32289463
Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity.
Gendreau S, Berzero G, Tafani C, Raynouard I, Ricard D, Malfuson JV, Viala K, Debs R, Houillier C, Diamanti L, Marchioni E, Lenglet T, Ouzegdouh M, Bihan K, Gilardin L, Psimaras D. Gendreau S, et al. Among authors: ouzegdouh m. Acta Oncol. 2020 Apr;59(4):484-489. doi: 10.1080/0284186X.2020.1723163. Epub 2020 Mar 3. Acta Oncol. 2020. PMID: 32122210 No abstract available.
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO). Leblond V, et al. Among authors: ouzegdouh m. Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10. Leuk Lymphoma. 2017. PMID: 28395585 Clinical Trial.
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Souchet L, Levy V, Ouzegdouh M, Tamburini J, Delmer A, Dupuis J, Le Gouill S, Pégourié-Bandelier B, Tournilhac O, Boubaya M, Vargaftig J, Choquet S, Leblond V; FILO (French Innovative Leukemia Organization). Souchet L, et al. Among authors: ouzegdouh m. Am J Hematol. 2016 Aug;91(8):782-6. doi: 10.1002/ajh.24405. Epub 2016 Jun 3. Am J Hematol. 2016. PMID: 27135784 Free article.
Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S. Mamez AC, et al. Among authors: ouzegdouh m. Bone Marrow Transplant. 2016 Mar;51(3):358-64. doi: 10.1038/bmt.2015.280. Epub 2015 Nov 23. Bone Marrow Transplant. 2016. PMID: 26595076 Free article. Clinical Trial.